The cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early estrogen receptor-positive breast cancer: a systematic review
Archives of Medical Science · 08.07.2024
DOI: 10.5114/aoms/190743 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Medical Science, online erschienen am 08.07.2024. Verfasst von Ying X Gue und 4 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Live…. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Adjuvant endocrine therapy is a key treatment in oestrogen receptor positive early breast cancer (BC). For premenopausal women ovarian function suppression (OFS) in combination either tamoxifen or aromatase inhibitor (AI) is utilised in high-risk cases. The resultant suppression of circulating oestradiol from OFS could have adverse cardiovascular and metabolic effects, subsequently increasing the risk of cardiovascular disease. Our study highlights the potential cardio-metabolic impact endocrine therapy and OFS have on premenopausal women with BC. It also highlights the pressing need for standardisation of routine collection and recording of cardiometabolic history and risk factors as part of baseline assessment and adverse event reporting to better understand the cardiometabolic impact these treatment has on our patients. Further studies, with particular focus on baseline and subsequent development of cardiovascular risk factors are needed to explore the impact of these drugs on the cardiovascular health of these young women with BC
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
- School of Medicine, University of Liverpool, Liverpool, United Kingdom.
- Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, United Kingdom.
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom.
Zitieren
APA
Gue, Y. X., Lau, D., Shantsila, A., Lip, G. Y. H., & Palmieri, C. (2024). The cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early estrogen receptor-positive breast cancer: a systematic review. Archives of Medical Science. https://doi.org/10.5114/aoms/190743
Vancouver
Gue YX, Lau D, Shantsila A, Lip GYH, Palmieri C. The cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early estrogen receptor-positive breast cancer: a systematic review. Archives of Medical Science. 2024. doi:10.5114/aoms/190743
BibTeX
@article{Gue2024,
author = {Gue, Ying X and Lau, Dorothy and Shantsila, Alena and Lip, Gregory Y H and Palmieri, Carlo},
title = {The cardiovascular and metabolic effects of ovarian suppression in combination with tamoxifen or an aromatase inhibitor as adjuvant therapy for early estrogen receptor-positive breast cancer: a systematic review},
journal = {Archives of Medical Science},
year = {2024},
doi = {10.5114/aoms/190743}
}
EUVIMED